Navigation Links
Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
Date:9/5/2007

BRIDGEWATER, N.J., Sept. 5 /PRNewswire/ -- Results from an investigational study researching the use of PROCRIT(R) (Epoetin alfa) in medical, surgical and trauma patients admitted to an intensive care unit (ICU) were published in today's New England Journal of Medicine. The study was sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

The primary objective of the study was to determine whether administration of PROCRIT would decrease the number of critically ill patients who received a red blood cell (RBC) transfusion after admission to the ICU. There was no significant difference in the percentage of patients who received a RBC transfusion between the PROCRIT and placebo groups. However, the hemoglobin increase was greater in the PROCRIT group. Despite the lack of transfusion reduction, the study showed that treatment with PROCRIT significantly reduced mortality, particularly in trauma patients admitted to the ICU.

"The improvement in mortality findings are encouraging and this is a potentially important finding in this clinical setting," said Howard Corwin, M.D., Dartmouth-Hitchcock Medical Center, Hanover, NH.

Study Design

This study was a prospective, randomized, double-blind, placebo- controlled, multi-center trial of patients aged 18 years or older who were admitted to an ICU for two days or more with a hemoglobin (Hb) less than 12 grams per deciliter of blood (g/dL). A total of 1,460 patients received either PROCRIT (n=733) or placebo (n=727) via subcutaneous injection on the first day of the study. For patients who remained in the hospital, treatment was specified for a total of three weekly doses (days 1, 8 and 15).

The primary endpoint was the percent of patients receiving any RBC transfusion through day 29. Secondary endpoints were RBC units transfused through day 42, change in Hb from baseline to day 29 and mortality at days 29 and 140. Analyses by the prospectively identified admission groups
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  IQPC,s 19 th Software ... the chairman of the Summit Mr. Phani Bidarahalli , ... be joined by the expert speaker faculty including senior executive ... 11 – 12, at The Hotel Kabuki in ... available for download on the event website, which can be ...
(Date:5/5/2015)... , May 5, 2015 Big Market Research ... US, Europe , ( France , ... Spain , UK) and Japan . ... reviewed. The report provides the 5-year test volume and sales forecasts ... NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ...
(Date:5/5/2015)... Faced with fast economy and population growth, an ... China,s medical device industry has been growing rapidly ... have been Beijing , Shanghai ... cities. However, the entry of a large number of medical ... in first-tier cities increasingly saturated. How do medical device enterprises ...
Breaking Medicine Technology:Phani Bidarahalli from Wipro to chair the upcoming 19th Software Design for Medical Devices Summit in San Francisco 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 2MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 4
... 19, 2007 - Amgen,(NASDAQ: AMGN) today ... study", a,randomized, double-blind, placebo-controlled, multicenter Phase ... 600 previously untreated,patients with extensive-stage small-cell ... study demonstrated,no statistically significant difference in ...
... Biomolecular Sciences Conference, THE WOODLANDS, Texas, April ... that data was presented,today highlighting potential therapeutic ... at the Society for Biomolecular,Sciences 13th Annual ... discoveries were made in a collaboration,between Lexicon ...
Cached Medicine Technology:Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5
(Date:5/5/2015)... 2015 " QuickPick Travel ” was featured ... takes a look small, medium, and large businesses making an ... and a business expert, conducted the business review and shared ... up to three weeks of vacation for free. , Vacations ... and explore the world. And when people are preparing for ...
(Date:5/5/2015)... 2015 This year, PolyU researchers garnered ... Merit Awards, three Gold Medals and four Silver Medals ... as follows: , (1) Grand Prize and Gold Medal ... Fashion Design and Fitting, Principal Investigator: Dr Allan Chee-kooi ... industry relies very much on the “mannequin” for many ...
(Date:5/5/2015)... Information Innovators Inc. (“Triple-i”), ... government, today announced its acquisition of Creative ... exclusively to federal government customers through its highly ... health services, and program management support. The company ... a Third Party Assessment Organization (3PAO) for cloud ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 The brains ... accelerated aging that correlate with slower information processing, according ... Graduate School of Public Health . , The ... with type 1 diabetes for cognitive difficulties. If progressive, ... diabetes. The study, funded by the National Institutes ...
(Date:5/5/2015)... 05, 2015 Rare Genomics Institute ... new study aimed at determining how crowdfunding can promote ... an international non-profit providing rare disease patients with access ... to scientists and researchers, and help for payment of ... am excited to see how crowdfunding will not only ...
Breaking Medicine News(10 mins):Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 2Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 3Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 4Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2
... offers 50 percent smaller size, 20 percent less ... in portable equipment, DALLAS, March 24 ... market, Texas Instruments (TI) (NYSE: TXN ),today ... ends (AFEs) for,portable to high-end ultrasound diagnostic equipment. ...
... Medicare & Medicaid Services Accepts as Complete DNV,s ... Application for Hospital Deeming Authority, HOUSTON, March ... has informed DNV Healthcare that its application to,deem hospitals in ... complete and ready for formal review., If approved, DNV ...
... and vision care with ... medical coverage, DETROIT, March ... all rolled into one product package., The "package" is Community Blue ... that will launch April 1. Community,Blue Plus combines preventive dental and vision ...
... Health care facilities, like all,Pennsylvania businesses, strive ... reducing workers, compensation expenses driven by claims made,against ... challenges,in the frequency and types of on the ... based law firm of Fried, Kane, Walters, Zuschlag,and ...
... and dementia patients and ... families regain what was once ... million Americans,including 250,000 Ohioans, struggle with the devastating effects ... the greater,Cleveland area offers new hope to Alzheimer,s patients ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... Ms. Nan Wang, Vice President, Ms. Helen Yang,International Business ... at the Brean Murray, Carret & Co. Fourth Investor ... p.m. China Standard Time at the,Grand Hyatt Hotel in ...
Cached Medicine News:Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 2Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 3Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 4Health News:DNV Healthcare Advances in Bid to Accredit Hospitals 2Health News:Blue Cross Blue Shield of Michigan Pioneers 'Total Body' PPO Product 2Health News:Reducing Cost of Health Care by Addressing Workers' Compensation Costs 2Health News:Cleveland Area Homewatch CareGivers Unveil New Alzheimer's Program 2Health News:Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China 2
... The Super 66® Stereo Fundus ... magnification viewing of the central retina. Its ... subtle macular and optic disc detail, making ... choroidal neovascular membranes, macular edema, serous detachments ...
... The original Volk 90D lens started the ... small 26mm diameter ring design which is ... Aspheric optical design expands the usable viewing ... Volk 90D has good small pupil capabilities, ...
The Volk 60D provides high magnification - making it ideal for detailed disc and macular viewing. Its 31mm diameter facilitates easy handling within the orbital area. Available with SupraCoat (argon...
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
Medicine Products: